Bacteriophages represent an innovative therapeutic approach that seeks to overcome the limitations of antibiotics by utilizing biological weapons (phages) that target multidrug-resistant bacteria. Following a 1.5 billion KRW investment in 2024, MicrobiotiX has attracted an additional 500 million KRW this time, bringing its cumulative investment to 2.9 billion KRW. The company has also completed a comprehensive platform equipped with a phage library, an in silico prediction module, and cGMP-grade manufacturing facilities.Financial TimesGlobeNewswire Korea's first bacteriophage clinical trial could mark a technological turning point in addressing the global crisis of antibiotic resistance. Phage therapy is gaining attention as a new pillar in strategies to combat resistant bacterial infections, owing to its safety and selectivity. Government support and investment attraction are highly significant, as they make the realization of such innovative therapies possible. However, phage therapy still faces challenges in terms of regulatory environment, long-term safety data, and large-scale production infrastructure. Nevertheless, MicrobiotiX's entry symbolizes the Korean bio-ecosystem's emergence as an international-level innovation leader.